ArticlePLOS global public health2025
Evaluation of the diagnostic accuracy of the ReLASV Pan-Lassa Antigen Rapid Test for Lassa Fever in Nigeria.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lassa fever is a zoonotic disease found in several countries across West Africa, with estimates of up to 300,000 infections and 10,000 deaths yearly. The highest incidence is in Nigeria. Suspected cases are often seen in areas with limited infrastructure and diagnostics capacity, hence the availability of an accurate rapid diagnostic test (RDT) that could be used in the community would be an important public health tool. Unfortunately, few RDTs for Lassa fever exist and have not been thoroughly validated. Toward that end, we conducted a Phase 2 performance evaluation to assess the diagnostic accuracy of the ReLASV Pan-Lassa Antigen Rapid Test (Zalgen Labs, Frederick, MD, USA) using archived, frozen whole blood, plasma, and serum samples collected from individuals in Nigeria to determine its suitability for widespread use as a screening tool for Lassa fever. The overall performance of this RDT was measured against the reference test, the Altona RealStar LASV real-time reverse transcription polymerase chain reaction 2.0 (Altona Diagnostics, Hamburg, Germany). The sensitivity and specificity of the ReLASV Pan-Lassa Antigen Test were 65% and 50.7%, respectively. The low diagnostic accuracy indicated in our and other independent evaluations of the ReLASV Pan-Lassa Antigen Rapid Test suggests that this test, at least until further developed, refined, and validated, is not suitable for making critical diagnostic or treatment decisions for Lassa fever, at least for lineages that commonly circulate in Nigeria. These findings underscore the importance of thoroughly assessing the performance characteristics of tests to ensure their reliability and accuracy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.